Long-term remission after upfront autologous hematopoietic stem cell transplant for CD5⁺ diffuse large-B cell lymphoma

References

• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–242. doi:10.1056/NEJMoa011795.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the groupe d‘Etudes des lymphomes de l‘Adulte. Blood. 2010;116(12):2040–2045. doi:10.1182/blood-2010-03-276246.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Gascoyne RD. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood. 2015;125(1):22–32. doi:10.1182/blood-2014-05-577189.
   PubMed Web of Science ®Google Scholar
• Younes A, Sehn LH, Johnson P, et al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-Germinal center B-cell diffuse large B-cell lymphoma. J Clin Oncol. 2019;37(15):1285–1295. doi:10.1200/JCO.18.02403.
   PubMed Web of Science ®Google Scholar
• Wilson WH, Wright GW, Huang DW, et al. Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL. Cancer Cell. 2021;39(12):1643–1653.e3. doi:10.1016/j.ccell.2021.10.006.
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503–511. doi:10.1038/35000501.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–282. doi:10.1182/blood-2003-05-1545.
   PubMed Web of Science ®Google Scholar
• Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378(15):1396–1407. doi:10.1056/NEJMoa1801445.
   PubMed Web of Science ®Google Scholar
• Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679–690. doi:10.1038/s41591-018-0016-8.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Seto M, Okamoto M, et al. De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood. 2002;99(3):815–821. doi:10.1182/blood.v99.3.815.
   PubMed Web of Science ®Google Scholar
• Harada S, Suzuki R, Uehira K, et al. Molecular and immunological dissection of diffuse large B cell lymphoma: CD5+, and CD5- with CD10+ groups may constitute clinically relevant subtypes. Leukemia. 1999;13(9):1441–1447. doi:10.1038/sj.leu.2401487.
   PubMed Web of Science ®Google Scholar
• Suguro M, Tagawa H, Kagami Y, et al. Expression profiling analysis of the CD5+ diffuse large B-cell lymphoma subgroup: development of a CD5 signature. Cancer Sci. 2006;97(9):868–874. doi:10.1111/j.1349-7006.2006.00267.x.
   PubMed Web of Science ®Google Scholar
• Kaneko H, Shimura K, Horiike S, et al. Cytogenetic analysis of de novo CD5-positive diffuse large B-cell lymphoma. Asia Pac J Clin Oncol. 2011;7(4):346–350. doi:10.1111/j.1743-7563.2011.01432.x.
   PubMed Web of Science ®Google Scholar
• Sang W, Ma Y, Wang X, et al. Clinicopathologic features and genomic signature of De novo CD5 + diffuse large B-cell lymphoma: a multicenter collaborative study. Am J Surg Pathol. 2022;46(11):1533–1544. doi:10.1097/PAS.0000000000001957.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Nakamura N, Suzuki R, et al. De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients. Haematologica. 2008;93(8):1195–1202. doi:10.3324/haematol.12810.
   PubMed Web of Science ®Google Scholar
• Niitsu N, Okamoto M, Tamaru J-I, et al. Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma. Ann Oncol. 2010;21(10):2069–2074. doi:10.1093/annonc/mdq057.
   PubMed Web of Science ®Google Scholar
• Cooper A, Tumuluru S, Kissick K, et al. CD5 gene signature identifies diffuse large B-cell lymphomas sensitive to bruton’s tyrosine kinase inhibition. J Clin Oncol. 2023;42(4):467–480. doi:10.1200/JCO.23.01574.
   PubMedGoogle Scholar
• Stiff PJ, Unger JM, Cook JR, et al. Autologous transplantation as consolidation for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 2013;369(18):1681–1690. doi:10.1056/NEJMoa1301077.
   PubMed Web of Science ®Google Scholar
• Chiappella A, Martelli M, Angelucci E, et al. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. Lancet Oncol. 2017;18(8):1076–1088. doi:10.1016/S1470-2045(17)30444-8.
   PubMed Web of Science ®Google Scholar
• Schmitz N, Nickelsen M, Ziepert M, et al. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol. 2012;13(12):1250–1259. doi:10.1016/S1470-2045(12)70481-3.
   PubMed Web of Science ®Google Scholar
• Cortelazzo S, Tarella C, Gianni AM, et al. Randomized trial comparing R-CHOP versus high-dose sequential chemotherapy in high-risk patients with diffuse large B-cell lymphomas. J Clin Oncol. 2016;34(33):4015–4022. doi:10.1200/JCO.2016.67.2980.
   PubMed Web of Science ®Google Scholar
• Epperla N, Hamadani M, Reljic T, et al. Upfront autologous hematopoietic stem cell transplantation consolidation for patients with aggressive B-cell lymphomas in first remission in the rituximab era: a systematic review and meta-analysis. Cancer. 2019;125(24):4417–4425. doi:10.1002/cncr.32464.
   PubMed Web of Science ®Google Scholar
• Miyazaki K, Asano N, Yamada T, et al. DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 study. Haematologica. 2019;105(9):2308–2315. doi:10.3324/haematol.2019.231076.
   Web of Science ®Google Scholar
• Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013;48(3):452–458. doi:10.1038/bmt.2012.244.
   PubMed Web of Science ®Google Scholar
• Sugimoto M, Ito S, Mashima K, et al. Retrospective evaluation of the MEAM regimen as a conditioning regimen before autologous peripheral blood stem cell transplantation for lymphoma in two centers with different dosing schedules of melphalan. Ann Hematol. 2016;95(9):1513–1519. doi:10.1007/s00277-016-2740-9.
   PubMed Web of Science ®Google Scholar
• Xu-Monette ZY, Tu M, Jabbar KJ, et al. Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries. Oncotarget. 2015;6(8):5615–5633. doi:10.18632/oncotarget.3479.
   PubMedGoogle Scholar
• Kato K, Ohno Y, Kamimura T, et al. Long-term remission after high-dose chemotherapy followed by auto-SCT as consolidation for intravascular large B-cell lymphoma. Bone Marrow Transplant. 2014;49(12):1543–1544. doi:10.1038/bmt.2014.189.
   PubMed Web of Science ®Google Scholar
• Schrader AMR, Jansen PM, Willemze R, et al. High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma. Blood. 2018;131(18):2086–2089. doi:10.1182/blood-2017-12-822817.
   PubMed Web of Science ®Google Scholar
• Alinari L, Gru A, Quinion C, et al. De novo CD5+ diffuse large B-cell lymphoma: adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort. Am J Hematol. 2016;91(4):395–399. doi:10.1002/ajh.24299.
   PubMed Web of Science ®Google Scholar
• Orellana-Noia VM, Reed DR, McCook AA, et al. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. Blood. 2022;139(3):413–423. doi:10.1182/blood.2021012888.
   PubMed Web of Science ®Google Scholar
• Wilson MR, Eyre TA, Kirkwood AA, et al. Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients. Blood. 2022;139(16):2499–2511. doi:10.1182/blood.2021014506.
   PubMed Web of Science ®Google Scholar
• Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022;386(4):351–363. doi:10.1056/NEJMoa2115304.
   PubMed Web of Science ®Google Scholar
• Jantunen E, Canals C, Rambaldi A, et al. Autologous stem cell transplantation in elderly patients (> or =60 years) with diffuse large B-cell lymphoma: an analysis based on data in the european blood and marrow transplantation registry. Haematologica. 2008;93(12):1837–1842. doi:10.3324/haematol.13273.
   PubMed Web of Science ®Google Scholar
• Sun L, Li S, El-Jawahri A, et al. Autologous stem cell transplantation in elderly lymphoma patients in their 70s: outcomes and analysis. Oncologist. 2018;23(5):624–630. doi:10.1634/theoncologist.2017-0499.
   PubMed Web of Science ®Google Scholar
• Dahi PB, Lee J, Devlin SM, et al. Toxicities of high-dose chemotherapy and autologous hematopoietic cell transplantation in older patients with lymphoma. Blood Adv. 2021;5(12):2608–2618. doi:10.1182/bloodadvances.2020004167.
   PubMed Web of Science ®Google Scholar
• Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel as Second-Line therapy for large B-cell lymphoma. N Engl J Med. 2022;386(7):640–654. doi:10.1056/NEJMoa2116133.
   PubMed Web of Science ®Google Scholar
• Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2022;387(24):2220–2231. doi:10.1056/NEJMoa2206913.
   PubMed Web of Science ®Google Scholar
• Budde LE, Sehn LH, Matasar M, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022;23(8):1055–1065. doi:10.1016/S1470-2045(22)00335-7.
   PubMed Web of Science ®Google Scholar
• Abramson JS, Solomon SR, Arnason J, et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood. 2023;141(14):1675–1684. doi:10.1182/blood.2022018730.
   PubMed Web of Science ®Google Scholar